CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a human experimental infection study with respiratory syncytial virus (RSV) designed to establish a safe and reliable RSV infection of the upper respiratory tract in adult volunteers. Upon determination of the optimal level of RSV inoculum, Alnylam plans to initiate a subsequent clinical protocol to evaluate the anti-viral activity for ALN-RSV01, an RNAi therapeutic being developed for the treatment of RSV infection. ALN-RSV01 is the industry’s most advanced RNAi therapeutic program for the treatment of an infectious disease and is an Alnylam proprietary program.
